ProCE Banner Activity

CDK4/6 Inhibitors in the Management of HR+/HER2- MBC

Slideset Download
Download this slideset to review the latest clinical data informing optimal use of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer, including an overview of resistance to these agents.

Released: December 11, 2019

Expiration: December 09, 2020

Share

Faculty

Eric P. Winer

Eric P. Winer, MD

Director, Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Immunomedics

Lilly

Faculty Disclosure

Primary Author

Eric P. Winer, MD

Director, Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts